

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: UCSD-06555

Serial No.: 09/307,223

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Judith A. Varner

(37 CFR § 1.98(b))

Filing Date: May 7, 1999

Group Art Unit: 1642

OTHER DOCUMENTS (Including Paper, Title, Date, Relevant Pages, Place of Publication)

24	Wierzbicka-Potynowski <i>et al.</i> (1999) "Structural requirements of Echistatin for the Recognition of $\alpha_v\beta_3$ and $\alpha_5\beta_1$ Integrins," J. Biol. Chem. 274:37809-14
25	Yi and Ruoslahti (2001) "A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis," Proc. Natl. Acad. Sci. 98:620-624
26	Varner <i>et al.</i> (1995) "Integrin $\alpha_5\beta_1$ Expression Negatively Regulates Cell Growth: Reversal by Attachment to Fibronectin," Mol. Biol. Cell 6:725-740
27	Morla <i>et al.</i> (1994) "Superfibronectin is a functionally distinct form of fibronectin," Nature 367:193-198
28	Kim <i>et al.</i> (2000) "Regulation of Angiogenesis <i>in Vivo</i> by Ligation of Integrin $\alpha_5\beta_1$ with the Central Cell-Binding Domain of Fibronectin," Am. J. Pathol. 156:1345-1362
29 <input checked="" type="checkbox"/>	Pasqualini <i>et al.</i> (1996) "A polymeric form of fibronectin has antimetastatic effects against multiple tumor types," Nature Med. 2:1197-1203
30 <input checked="" type="checkbox"/>	Kumar <i>et al.</i> (1997) "Biochemical Characterization of the Binding of Echistatin to Integrin $\alpha_v\beta_3$ Receptor," J. Pharmacol. Experimen. Therap. 283:843-853
31 <input checked="" type="checkbox"/>	Nowlin <i>et al.</i> (1993) "A Novel Cyclic Pentapeptide Inhibits $\alpha_4\beta_1$ and $\alpha_5\beta_1$ Integrin-mediated Cell Adhesion," J. Biol. Chem. 268:20352-20359
32 <input checked="" type="checkbox"/>	Takagi <i>et al.</i> (1997) "Structural Interlock between Ligand-Binding Site and Stalk-Like Region of β_1 Integrin Revealed by a Monoclonal Antibody Recognizing Conformation-Dependent Epitope," J. Biochem. 121:914-921
33 <input checked="" type="checkbox"/>	Kim <i>et al.</i> (2002) "Inhibition of endothelial cell survival and angiogenesis by protein kinase A," J. Clin. Invest. 110:933-941
34	Clark <i>et al.</i> (1982) "Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing," J Invest Dermatol. Nov;79(5):269-76
35	Castellani <i>et al.</i> (1994) "The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis," Int J Cancer. 59:612-618
36	Neri <i>et al.</i> (1997) "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform," Nat Biotechnol. Nov;15(12):1271-5
37	Mariani <i>et al.</i> (1997) "Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants, Cancer. Dec 15;80(12 Suppl):2378-84
38	Pasqualini <i>et al.</i> (1996) "A polymeric form of fibronectin has antimetastatic effects against multiple tumor types," Nature Medicine 2(1):1197-1203; page 1197, column 2, last paragraph
39	Kumar <i>et al.</i> (1997) "Biochemical characterization of the binding of echistatin to integrin $\alpha_v\beta_3$ receptor," Journal of Pharmacology and Experimental Therapeutics, 283(2):843-853

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: UCSD-06555

Serial No.: 09/307,223

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Separate Sheets If Necessary)

Applicant: Judith A. Vamer

Filing Date: May 7, 1999

Group Art Unit: 1642

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
See	1	5,922,676	7/13/99	Pasqualini <i>et al.</i>			
	2	5,567,417	10/22/96	Sasisekharan <i>et al.</i>			
	3	5,866,540	2/2/99	Jonczyk <i>et al.</i>			
↓	4	6,177,542	1/23/01	Ruoslahti <i>et al.</i>			

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
See	5	WO 95/14714	1/6/95 ✓	PCT				
↓	6	WO 93/15203	8/5/93 ✓	PCT				
	7	WO 96/04304	2/15/96 ✓	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

See	8	Thorpe in <i>Monoclonal Antibodies in Biological and Clinical Applications</i> , Pinchera <i>et al.</i> , eds, 1995, pages 475-506						
	9	Gallin <i>et al.</i> in <i>Inflammation: Basic Principles and Clinical Correlates</i> , Raven Press, NY, 1988, page 552						
	10	Takada <i>et al.</i> (1988) "Extracellular Matrix Receptors, ECMRII and ECMRI, for Collagen and Fibronectin correspond to VLA-2 and VLA-3 in the VLA Family of Heterodimers," <i>J. Cell. Biochem.</i> 37:385-393						
	11	Takada <i>et al.</i> (1987) "Fibronectin receptor structures in the VLA family of heterodimers," <i>Nature</i> 326:607-609						
	12	Elices <i>et al.</i> (1991) "Receptor Functions for the Integrin VLA-3: Fibronectin, Collagen, and Laminin Binding are Differentially Influenced by Arg-Gly-Asp Peptide and by Divalent Cations," <i>J. Cell Biol.</i> 112:169-181						
	13	Masumoto & Hemler (1993) "Multiple activation states of VLA-4. Mechanistic differences between adhesion to CS1/fibronectin and to vascular cell adhesion molecule-1," <i>J. Biol. Chem.</i> 268:228-234						
	14	Zhang <i>et al.</i> (1993) "The $\alpha\beta$ 1 Integrin Functions as a Fibronectin Receptor But Does Not Support Fibronectin Matrix Assembly and Cell Migration on Fibronectin," <i>J. Cell Biol.</i> 122:235-242						
	15	Ruegg <i>et al.</i> (1992) "Role of integrin $\alpha 4\beta 7/\alpha 4\beta P$ in Lymphocyte Adherence to Fibronectin and VCAM-1 and in Homotypic Cell Clustering," <i>J. Cell Biol.</i> 117:179-189						
	16	Orlando and Cheresch (1991) "Arginine-Glycine-Aspartic Acid Binding Leading to Molecular Stabilization Between Integrin $\alpha_3\beta_3$ and Its Ligand," <i>J. Biol. Chem.</i> 266:19543-19550						
	17	Suehiro <i>et al.</i> (1997) "Fibrinogen is a Ligand for Integrin $\alpha_3\beta_1$ on Endothelial Cells," <i>J. Biol. Chem.</i> 272:5360-5366						
	18	Suehiro <i>et al.</i> (2000) "Fibrinogen Binds to Integrin $\alpha_3\beta_1$ via the Carboxyl-Terminal RGD site of the α -chain," <i>J. Biochem.</i> 128:705-710						
	19	Felding-Haberman <i>et al.</i> (1997) "A Single Immunoglobulin-like Domain of the Human Neural Cell Adhesion Molecule L1 Supports Adhesion by Multiple Vascular and Platelet Integrins," <i>J. Cell Biol.</i> 139:1567-1581						
	20	Silletti <i>et al.</i> (2000) "Plasmin Sensitive Dibasic Sequences in the Third Fibronectin-like Domain of L-cell Adhesion Molecule (CAM) Facilitate Homomultimerization and Concomitant Integrin Recruitment," <i>J. Cell Biol.</i> 149:1485-102						
	21	Rehn <i>et al.</i> (2001) "Interaction of endostatin with integrins implicated in angiogenesis" <i>Proc. Natl. Acad. Sci.</i> 98:1024-1029						
	22	Carlson <i>et al.</i> (2001) "Direct Cell Adhesion to the Angiopoietins Mediated by Integrins," <i>J. Biol. Chem.</i> 276:26516-26525						
↓	23	Marekiewicz <i>et al.</i> (1999) "Structural and Functional Characterization of EMF10, a Heterodimeric Disintegrin from <i>Eristocophis macmahoni</i> Venom that Selectively Inhibits $\alpha_3\beta_1$ Integrin" <i>Biochem.</i> 38:13302-13309						

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.